Sevo Nutraceuticals’ flagship product, PERCEPTIV™, addresses one of the most significant issues of wellbeing facing the United States—cognitive health.
Waltham, MA (PRWEB) March 20, 2014
Sevo Nutraceuticals, Inc. announced that it has been nominated for the 2014 SBANE New England Innovation Awards. The Innovation Awards showcase the best innovative companies in the region that possess the growth potential to expand the New England economic base.
Sevo Nutraceuticals’ flagship product, PERCEPTIV™, addresses one of the most significant issues of wellbeing facing the United States—cognitive health. The cost of addressing this issue in America is soon expected to top $1 trillion a year. Cognitive health impacts the largest demographic in America—the Baby Boomers—who number 74 million, according to US Census data. Based on a report by the National Council on Aging, Americans are twice as fearful of losing mental capacity as having diminished physical ability and 60% of adults are very or somewhat worried about memory loss. These factors point to a growing need for readily available brain health products that are both safe and effective.*
PERCEPTIV is patented and based on seven independent, national clinical studies performed by UMASS Lowell professor Dr. Thomas Shea and his team, in which the supplement improved cognitive performance not only for healthy adults but also for those with cognitive impairment. The claims of the patent protect the use of the unique formulation of PERCEPTIV in the large and growing segment of brain health and cognitive performance supplements.
About Sevo Nutraceuticals, Inc.
Sevo Nutraceuticals, Inc. was established in 2012 to license and market science-based nutraceuticals. Its vision is to become a market leader in highly efficacious, scientifically researched nutraceuticals that improve people's lives. The Company's mission is to build a select portfolio of high value products with clear markets which are leaders in their category.
Sevo’s cornerstone product, PERCEPTIV™, was licensed from UMass Lowell in 2012 and was developed under the leadership of UMass Lowell Professor Thomas B. Shea, Director of the Center for Cellular Neurobiology and Neurodegeneration Research.
Sevo Nutraceuticals, Inc. is a VIC Technology Venture Development™ portfolio company.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.